Gallbladder & Bile Duct Cancer Treatment in Hyderabad

Overview

Understanding Gallbladder & Bile Duct Cancer

Gallbladder cancer (GBC) and cholangiocarcinoma (cancer of the bile ducts) are the two most common biliary tract malignancies. India has particularly high rates of GBC in certain regions — the Indo-Gangetic belt and Andhra Pradesh — likely related to cholelithiasis (gallstones) prevalence, Salmonella infection, and genetic factors. GBC is often discovered incidentally after cholecystectomy for “benign” gallstones.

Cholangiocarcinoma is classified by anatomical location: intrahepatic (within the liver), perihilar/Klatskin tumour (at the hepatic duct confluence — the most common, most complex), and distal cholangiocarcinoma (in the common bile duct). Each requires a different surgical strategy. Perihilar cholangiocarcinoma requires detailed biliary anatomy delineation with MRCP and hepatic volumetry before planning resection.

The only curative treatment for biliary tract cancers is surgical resection with clear margins. Unfortunately, most patients present with advanced or unresectable disease — emphasising the importance of specialist evaluation for every potentially operable case. Small tumours found incidentally (T1a GBC in the muscle layer) may be cured by cholecystectomy alone; T1b and T2+ require re-resection with liver bed excision and lymphadenectomy.

At a Glance

Types: Gallbladder cancer, intrahepatic, perihilar, distal cholangiocarcinoma
India incidence: High — particularly Andhra Pradesh, UP, Bihar (GBC)
Risk factors: Gallstones, PSC, choledochal cyst, liver fluke infection (Asia)
Key staging tool: MRCP, CT, PET — resectability determined by vascular involvement
Curative surgery: Extended cholecystectomy, bile duct resection, hepatectomy

Warning Signs

Symptoms of Gallbladder & Bile Duct Cancer

Biliary tract cancers are often diagnosed late — painless jaundice is the classic presentation and should always trigger urgent investigation.

💛
Painless Obstructive Jaundice

Yellow skin/eyes from biliary obstruction — the most common presenting symptom.

😣
Right Upper Quadrant Pain

Dull or colicky right upper abdominal pain, sometimes radiating to the back.

⚖️
Weight Loss & Anorexia

Significant unintentional weight loss and poor appetite.

🌡️
Fever & Rigors

Charcot’s triad (jaundice, fever, RUQ pain) suggests cholangitis — urgent treatment needed.

📊
Elevated CA19-9 / CEA

Raised tumour markers on routine blood tests — requires imaging investigation.

🔍
Incidental Finding

Gallbladder cancer discovered in the pathology specimen after laparoscopic cholecystectomy for “benign” stones.

Our Approach

Surgical Treatment of Biliary Cancers

For gallbladder cancer, the extent of resection depends on T-stage. T1a: simple cholecystectomy is curative. T1b–T2: requires re-resection with a 2 cm margin of liver bed (segments IVb and V), portal lymphadenectomy, and bile duct resection if involved. T3–T4: more extensive hepatectomy with vascular reconstruction in selected cases. Patients who had laparoscopic cholecystectomy for GBC require re-staging and re-resection at a specialist centre.

For perihilar cholangiocarcinoma (Klatskin tumours), resection requires an extended hepatectomy (right or left), total bile duct excision, and biliary reconstruction with a Roux-en-Y hepaticojejunostomy. Pre-operative portal vein embolisation may be needed to ensure adequate future liver remnant. Bismuth-Corlette classification guides the extent of resection.

For distal cholangiocarcinoma, a Whipple’s procedure (pancreaticoduodenectomy) is performed. All biliary tract cancers benefit from adjuvant capecitabine chemotherapy after resection (BILCAP trial). FGFR2 inhibitors (for intrahepatic CC with FGFR2 fusions) and IDH1 inhibitors represent targeted therapy options in the palliative setting.

Surgical Procedure
Liver Metastases & Hepatic Resection

Extended hepatectomy for gallbladder and intrahepatic cholangiocarcinoma requiring liver resection.

Learn more →

Surgical Procedure
Whipple’s Procedure

Pancreaticoduodenectomy for distal cholangiocarcinoma of the common bile duct.

Learn more →

Why Choose Us

Expertise You Can Trust

Dr. Mohammed Imaduddin brings internationally trained surgical skills and a patient-first philosophy to every case.

500+
Complex Oncological Surgeries Performed
15+
Years in Surgical Oncology
3
International Training Centres (Hannover, Charité, AIIMS)
FACS
Fellow of the American College of Surgeons

Common Questions

Frequently Asked Questions

Questions commonly asked by patients with gallbladder and bile duct cancer.

I had my gallbladder removed for stones and the pathology showed cancer — what now?
This is a well-recognised scenario — incidental gallbladder cancer (IGBC). What happens next depends on the T-stage reported in the pathology. T1a (confined to mucosa) — simple cholecystectomy is curative, no further surgery needed. T1b (into muscularis) — re-resection of liver bed and lymphadenectomy is recommended. T2+ — re-resection is mandatory at a specialist centre. Please do not delay — come for evaluation as soon as possible after the pathology report.
Does laparoscopic cholecystectomy increase the risk of spreading gallbladder cancer?
Yes — if gallbladder cancer is present and the gallbladder is perforated or bile spills during laparoscopic surgery, cancer cells can seed the abdominal cavity and port sites. This is why laparoscopic surgery for “benign” gallstones should be done carefully without gallbladder perforation. If IGBC is detected post-operatively, CT/PET staging and specialist evaluation are needed to assess for port site metastases and plan re-resection.
What is the prognosis for gallbladder cancer?
Prognosis varies greatly by stage. T1a: near 100% 5-year survival. T1b–T2 with complete R0 resection: 60–80%. T3 with major hepatectomy: 30–40%. T4 (unresectable): median survival 6–12 months with chemotherapy. The key determinant is whether R0 resection is achieved — which requires referral to a specialist centre.
What is PSC and does it increase cholangiocarcinoma risk?
Primary sclerosing cholangitis (PSC) is an autoimmune condition causing progressive inflammation and scarring of the bile ducts. It carries a lifetime risk of cholangiocarcinoma of 10–20%. Patients with PSC should be under regular specialist surveillance with MRCP, CA19-9, and brush cytology. Rising CA19-9 or new strictures on MRCP should trigger urgent evaluation for cholangiocarcinoma.
What chemotherapy is used for unresectable biliary cancer?
The standard first-line regimen for unresectable biliary tract cancer (gallbladder cancer, cholangiocarcinoma) is gemcitabine + cisplatin (GemCis), based on the ABC-02 trial. The addition of durvalumab (immunotherapy) to GemCis improved outcomes in the TOPAZ-1 trial and is now recommended in first-line. For FGFR2 fusion-positive intrahepatic CC, pemigatinib or futibatinib are targeted therapy options. IDH1-mutated intrahepatic CC responds to ivosidenib.

Ready to Discuss Your Case?

Every cancer journey is different. I offer a detailed, unhurried consultation to help you understand your options and make informed decisions.